Consonance Capital Management LP Immuno Gen, Inc. Transaction History

Consonance Capital Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$5.79 - $8.6 $4.07 Million - $6.05 Million	-703,790 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$6.5 - $10.53 $18.3 Million - $29.6 Million	-2,812,154 Reduced 79.98%	703,790 $5.7 Million
Q4 2020 Feb 16, 2021	BUY	$3.7 - $7.66 $13 Million - $26.9 Million	3,515,944 New	3,515,944 $22.7 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Consonance Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Consonance Capital Management LP with notifications on news.